CVRX - Key Persons

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Compensation Committee
• New Enterprise Associates

Ali joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor's degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.

Job Titles:

• Senior Vice President of US Sales

Craig Palmer is the Senior Vice President of US Sales, possessing over 20 years of pharmaceutical, bio-technology, and cardiovascular medical device field experience. Prior to joining CVRx®, Mr. Palmer was responsible for launching and developing the markets for key cardiovascular therapies, such as Carvedilol, Ranolazine, Implantable Cardiac Defibrillators, Pacemakers, and Cardiac Resynchronization Therapies. After graduating with a Bachelor of Science from The Pennsylvania State University, Mr. Palmer has had the privilege of working with some of the elite organizations of the industry, including GlaxoSmithKline, Gilead, Boston Scientific, and St. Jude Medical.

Job Titles:

• Vice President of Regulatory Affairs and Quality Assurance

Mr. Bruhn-Ding has over 36 years of experience in the medical device industry. He has held positions at St. Jude Medical, Guidant and Angeion in research, product development, regulatory affairs, quality assurance, and clinical affairs. Most recently prior to CVRx®, Dean was the Vice President of Regulatory Affairs for St. Jude Medical (SJM), Cardiology Division and held other Vice President and Director positions at the SJM Daig Division in Regulatory Affairs, Clinical Affairs, and Quality Assurance. Dean earned his undergraduate degree in Medical Technology from North Dakota State University.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit Committee

Geoff Pardo joined Gilde Healthcare in 2011 as a Partner leading the U.S. investment activities in Boston/Cambridge, MA. He led the investments in Ablative Solutions, Inari Medical (NASDAQ: NARI), Axonics Modulation Technologies (NASDAQ: AXNX), CVRx, Vesper Medical, InovaLabs (acquired by ResMed), BionX (acquired by Ottobock) and Vapotherm (NYSE: VAPO) and represents Gilde as a member of the board of directors for each company. Previously, he was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience (sold to J&J) and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics. Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. He has also worked at Cardinal Partners as an Associate leading their investing activities in the medical device sector. Geoff began his career in medical devices as a product manager with Synthes USA. He has a B.A. with honors in History from Brown University and an M.B.A. from the Wharton School of Business. He is a US citizen based in Gilde Healthcare's Cambridge, MA office.

Job Titles:

• Chief Strategy Officer

Mr. Brintnall has 45 years of business experience and has been the head of finance at six emerging growth companies (three in technology and three in medical devices) including Computer Network Technology, Integ, and Survivalink. John has an undergraduate degree in Finance from the University of Notre Dame.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Nominating and Corporate Governance Committee
• Special Partner of NEA

John M. Nehra graduated from the University of Michigan, BA 1970. Upon graduating, he joined Doyle O'Connor & Company, a leading nationwide NASDAQ trading firm based in Chicago, as an Associate in their Venture Group. In 1971 Mr. Nehra built a small Research and Sales Department following small to medium sized publicly traded growth stocks, complementing the firm's historic trading capabilities. With the passing of Bob Doyle in 1975, the firm never fully realized its full potential. In 1975 Alex Brown & Sons hired Mr. Nehra to build a corporate strategy in Health Care, with an expanded approach to Investment Banking. For decades Alex. Brown became the preeminent national firm in Health Care Research, Trading and Banking. Alex. Brown adopted this strategic template in Software, Transportation, Consumer and Financial Services. In 1981 Mr. Nehra became a Partner of the firm. Mr. Nehra also worked with Alex Brown's Partners with an entry into Venture Capital, Merchant Banking and Capital Markets. Mr. Nehra worked and managed Health Care related Research and Investment Banking ultimately managing the Capital Markets Desk. In 1989 until his retirement in August 2014, Mr. Nehra was affiliated with New Enterprise Associates ("NEA"), a leading venture capital firm, including, from 1993 until his retirement, as General Partner of several of its affiliated venture capital limited partnerships. Mr. Nehra also served as Managing General Partner of Catalyst Ventures, a venture capital firm, from 1989 to 2013. Mr. Nehra served on numerous boards of NEA's portfolio companies in healthcare and technology until his retirement in August 2014. Mr. Nehra remains a retired special partner of NEA. Since 1999 Mr. Nehra has served on the board of DaVita (NYSE:DVA). He advises and is on the board of several private companies. He has been active with the Baltimore School for the Arts and various charities. Mr. Nehra is married and has two daughters.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit Committee

Mr. Slattery serves on the Board of Replimune Group, Inc., Morphic Therapeutic and CVRx®. He previously served as the Executive Vice President and Chief Financial Officer of TransEnterix, Inc. from October 2013 through December 2019. Mr. Slattery served as Executive Vice President and Chief Financial Officer of Baxano Surgical, Inc. from April 2010 until September 2013. Mr. Slattery served as a member of the Baxano Surgical Board of Directors from November 2007 until April 2010 and resigned in connection with his appointment as an officer. From February 1996 through August 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, a molecular diagnostics company that was acquired by Qiagen, N.V. in August 2007, including from October 2006 through August 2007 as Chief Financial Officer and Senior Vice President of Finance and Information Systems. Mr. Slattery served on the Board of Directors of Micromet, Inc., a publicly-held biopharmaceutical company, and Exosome Diagnostics, Inc., a privately-held molecular diagnostics company. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit Committee
• Managing Partner at Vensana Capital

Kirk Nielsen has served as one of our directors since July 2020. Mr. Nielsen has been a Managing Partner at Vensana Capital, a medtech-focused investment firm, since January 2019, and a Managing Director of Versant Ventures, a healthcare-focused venture capital firm, since January 2011. He currently serves on the board of directors of public company Inari Medical, Inc. and as a board member for several private companies, including: Alleviant Medical, Metavention, Monteris Medical, and SpyGlass Ophthalmics. Mr. Nielsen received an A.B. from Harvard College and an M.B.A. from Harvard Business School.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Compensation Committee
• Miach Orthopaedics As the President and Chief Executive Officer

Martha Shadan joined Miach Orthopaedics as the president and chief executive officer in January 2019. During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company's acquisition by Smith & Nephew in December 2017. Martha Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations. Prior to joining Rotation Medical, Martha was the president of the Trauma Division at Zimmer where she managed the P&L for the global business. Martha served at Covidien as vice president/general manager of Vascular Therapies and vice president/general manager BioSurgery and Sports Surgery. Other companies that have benefited from Martha's experience and leadership include Bristol Myers Squibb Co. and Merck Millipore. Martha is the chairwoman of the Board of Directors for a medical device start-up, IlluminOss. She is actively involved with the Advanced Medical Technology Association (AdvaMed), serving on the Board of Directors since 2017; being a member of the Accel Board of Directors since 2015 and currently serving as its chairwoman. Accel is the division within AdvaMed dedicated to addressing the unique needs and challenges of smaller medical technology manufacturers. Martha chairs the Diversity and Inclusion Committee for AdvaMed and is a founding member of the Leadership Circle for the Women's Executive Network (WEN). She is also a board advisor for several other companies. Martha holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.

Job Titles:

• Member of the Board of Directors

Job Titles:

• Vice President of Global Clinical Research

Ms. Liz Galle has over 20 years of cardiovascular clinical trial experience. Prior to coming to CVRx®, she lead statistical and clinical scientist groups at Guidant (Boston Scientific Cardiac Rhythm Management) and was involved in the Women's Health Initiative Study while at the Fred Hutchinson Cancer Research Center. Liz earned a masters degree in biostatistics from Yale University School of Public Health.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Compensation Committee
• Founding General Partner of Treo Ventures

Mudit is a Founding General Partner of Treo Ventures, and the CEO and co-founder of NuXcel, a medical device accelerator. Mudit also co-founded and serves as Chairman of the Board of ShiraTronics, Inc., a NuXcel spin off company. Mudit has over two decades of medical device industry experience across company formation, R&D, and business development. In addition to his private venture capital experiences at Treo Ventures, and Synergy Life Science Partners, Mudit also brings a strategic investment perspective based on his tenure at Johnson and Johnson Development Corporation. Mudit has served on the boards of several medical device companies, from early to commercial growth stage, resulting in successful IPOs and M&A transactions. Mudit current serves on the boards of Inspire Medical Systems (NYSE: INSP), Neochord, Inc., ShiraTronics, Inc., CVRx, Inc., and Noctrix, Inc. Some of his prior investments/board responsibilities include Irhythm Technologies (NSDQ:IRTC), Aptus Endosystems (Acqd. by Medtronic), CardioMEMS (Acqd. by St. Jude Medical), Impres Medical (Acqd. by J&J), and Neuspera, Inc. Mudit also serves on the Board of Visitors of the Graduate School at Duke University, External Advisory Board of John Hopkins University Center for Bioengineering Innovation and Design. Prior to his investing career, Mudit held operational roles in the Cardiac Rhythm Management Division of Guidant Corporation, and played a key role in developing novel device technologies for heart failure, remote cardiac monitoring, and cardiac ablation. Mudit holds 8 issued patents and has authored several peer reviewed publications. Mudit graduated with a B.E. in Electrical Engineering from REC, Nagpur, India, where he was a gold medal recipient for academic achievements. He received his Ph.D. in Biomedical Engineering from Duke University, and his M.B.A. from the Wharton School, University of Pennsylvania.

Job Titles:

• Vice President of European Sales and Marketing

Mr. Hengsteler has over 25 years of management experience in sales & marketing functions in Germany and throughout Europe in the Medical Technology Field. Prior to joining CVRx®, he held various sales & marketing leadership roles in 3 international companies in the medical device sector (St. Jude Medical, Sorin Group and Boston Scientific) focusing on the field of Cardiac Rhythm Management (Pacemakers, ICDs and Cardiac Resynchronization Therapy) and Electrophysiology (EP catheters and recording, 3D mapping and cryoablation). After graduating with a Diploma in physics from Ulm University, Germany, Mr. Hengsteler finished his education with a Dr. rer. nat. in physics at Ulm University, Germany.